Message From Local Pharmacy Team

March 1, 2023 updated by: University of Pennsylvania
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a control message telling patients that an updated COVID booster vaccine is waiting for them. The intervention testing if text messages encouraging vaccination that come from a patient's local pharmacy team will produce more vaccinations than otherwise identical messages.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

520000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • University of Pennsylvania

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Exclusion Criteria:

  1. The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
  2. The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Message from local pharmacy team
This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.
Behavioral: COVID Booster text messages
Participants will receive text messages per descriptions listed in the arms
Experimental: Control condition with "waiting for you" message
This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
Behavioral: COVID Booster text messages
Participants will receive text messages per descriptions listed in the arms

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient uptake of COVID bivalent booster
Time Frame: During the 30 days after receiving the SMS/MMS intervention
Whether patients receive a bivalent COVID booster at the pharmacy in question
During the 30 days after receiving the SMS/MMS intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient uptake of COVID bivalent booster
Time Frame: 60 days after receiving the SMS/MMS intervention
Whether patients receive a bivalent COVID booster at the pharmacy in question
60 days after receiving the SMS/MMS intervention
Patient uptake of COVID bivalent booster
Time Frame: 90 days after receiving the SMS/MMS intervention
Whether patients receive a bivalent COVID booster at the pharmacy in question
90 days after receiving the SMS/MMS intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2022

Primary Completion (Actual)

December 8, 2022

Study Completion (Actual)

February 6, 2023

Study Registration Dates

First Submitted

November 4, 2022

First Submitted That Met QC Criteria

November 4, 2022

First Posted (Actual)

November 14, 2022

Study Record Updates

Last Update Posted (Actual)

March 3, 2023

Last Update Submitted That Met QC Criteria

March 1, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 851911-Trial D

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on COVID Booster text messages

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe